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ABSTRACT 
METFORMIN, A CONVENIENT ALTERNATIVE TO INSULIN IN THE 
MANAGEMENT OF GESTATIONAL DIABETES MELLITUS. 
Introduction 
The prevalence of gestational diabetes is increasing as pregnant population is 
becoming older and obese. Women with GDM have increased rates of pregnancy 
complications and risks of type II diabetes later in life. The recent evidence from 
hyperglycemia and adverse pregnancy outcomes (HAPO) study shows that 
hyperglycemia below diagnostic levels for diabetes is similarly associated with 
adverse pregnancy outcomes. The benefit of treatment of GDM has been clarified in 
recent landmark studies. Lifestyle, diet and when indicated, insulin clearly improve 
outcomes in GDM. Women who begin insulin therapy require education to ensure 
safe administration on insulin. Use of insulin is also associated with hypoglycaemia 
and weight gain. The use of safe and effective oral agents may offer advantages over 
insulin.  
Oral metformin is the logical option for women with GDM, it improves insulin 
sensitivity by activating AMP kinase and is not associated with weight gain or 
hypoglycaemia. My hypothesis is that perinatal outcomes would be similar for both 
treatments that women would consider metformin as a treatment more acceptable than 
insulin, and that metformin would improve markers of insulin sensitivity in the mother 
and baby.  
Objective of Study 
To determine the effectiveness of metformin, a convenient alternative to insulin 
in management of GDM. 
Study Design -Prospective observational study 
Materials and Methods 
Sample size: 100 Antenatal mothers  
 Of these 60 were started on metformin and 40 were started on insulin.  
 Inclusion criteria: 
                      All antenatal mothers  
 Impaired GTT (140 – 200 mg/dl) 
 Singleton pregnancy 
Exclusion criteria 
  Pre pregnancy diagnosis of diabetes mellitus 
 Type I diabetes mellitus 
 Antenatal mothers diagnosed in first trimester 
 Multiple pregnancy 
 Patients with altered LFT and RFT 
Results 
 
A total of 100 patients were studied . about 60 patients were treated with 
metformin and 40 patients required insulin. out of the 60 patients in the metformin 
group about 11 mothers required supplemental insulin. the maternal and neonatal 
outcomes were compared. In the maternal outcomes the post treatment fasting and the 
post prandial gluciose levels shows not much of significance. However the maternal 
hypoglycaemia was noted in the insulin group which was not present in the metformin 
group. Weight gain compared between the two groups did not show any statistical 
significance. Many studies quotes that metformin is associated with less weight gain 
which was not noted in my study.  Associated conditions such as pre eclampsia, 
polyhydramnios, IUGR are equally present in both the treatment groups, hence no 
statistical significance. Regarding the neonatal outcomes, birth weight, NICU 
admissions, and neonatal hypoglycaemia were studied which showed no statistical 
significance between the two treatment groups. 
